1. Adelaide Research & Scholarship
  2. Schools and Disciplines
  3. School of Medicine
  4. Medicine
  5. Medicine publications
Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/120618
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShrestha, A.C.-
dc.contributor.authorWijesundara, D.K.-
dc.contributor.authorMasavuli, M.G.-
dc.contributor.authorMekonnen, Z.A.-
dc.contributor.authorGowans, E.J.-
dc.contributor.authorGrubor-Bauk, B.-
dc.date.issued2019-
dc.identifier.citationVaccines, 2019; 7(2)-
dc.identifier.issn2076-393X-
dc.identifier.issn2076-393X-
dc.identifier.urihttp://hdl.handle.net/2440/120618-
dc.description.abstractDNA vaccines present one of the most cost-effective platforms to develop global vaccines, which have been tested for nearly three decades in preclinical and clinical settings with some success in the clinic. However, one of the major challenges for the development of DNA vaccines is their poor immunogenicity in humans, which has led to refinements in DNA delivery, dosage in prime/boost regimens and the inclusion of adjuvants to enhance their immunogenicity. In this review, we focus on adjuvants that can enhance the immunogenicity of DNA encoded antigens and highlight the development of a novel cytolytic DNA platform encoding a truncated mouse perforin. The application of this innovative DNA technology has considerable potential in the development of effective vaccines-
dc.description.statementofresponsibilityAshish C. Shrestha, Danushka K. Wijesundara, Makutiro G. Masavuli, Zelalem A. Mekonnen, Eric J. Gowans and Branka Grubor-Bauk-
dc.language.isoen-
dc.publisherMDPI-
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).-
dc.source.urihttp://dx.doi.org/10.3390/vaccines7020038-
dc.subjectDNA vaccine; adjuvants; vaccine delivery; plasmid; cytolytic; perforin; bicistronic; HCV; HIV-
dc.titleCytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines-
dc.typeJournal article-
dc.identifier.doi10.3390/vaccines7020038-
dc.relation.grantNHMRC-
pubs.publication-statusPublished-
dc.identifier.orcidShrestha, A.C. [0000-0001-5049-8351]-
dc.identifier.orcidWijesundara, D.K. [0000-0002-0740-8362]-
dc.identifier.orcidMasavuli, M.G. [0000-0001-7287-6595]-
dc.identifier.orcidMekonnen, Z.A. [0000-0002-3705-4526]-
dc.identifier.orcidGowans, E.J. [0000-0002-4274-8311]-
dc.identifier.orcidGrubor-Bauk, B. [0000-0002-4642-105X]-
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_120618.pdfPublished version1.47 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.